← Therapy pipeline
Investigational · Obesity development

Berobenatide + MET233i

Pfizer / Metsera

Long-acting GLP-1 plus amylin/calcitonin activity.

GLP-1amylin
Obesity stagePhase 2Updated as of November 2026
SponsorPfizer / Metsera
TargetsGLP-1 + amylin
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Results availability

No numerical results shown

No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 2Initiated
Milestone → next

Latest: Pfizer lists the GLP-1/amylin combination in Phase 2 obesity development.

Next: Combination efficacy and tolerability data.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies1 record

Phase 2b

SOLIS-1

Combination weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with overweight or obesity; evaluates long-acting PF-08653945 (PF’3945) alone and in combination with berobenatide, including weekly/monthly regimens.